Stereotactic Body Radiation Therapy
Phase 2Small molecule
Stereotactic Body Radiation Therapy is one of 37 small molecule programs targeting Stereotactic Body Radiation Therapy. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Nano-Crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Anktiva
SSWOG Cancer Research Network
Phase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
Stereotactic Body Radiation Therapy
RRoswell Park Cancer Institute
Phase 2
Remeron
OOrganon and Co
Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer1 trial
Pancreatic Cancer1 trial
SBRT Plus vNKT for Pancreatic Cancer
Unknown status·—·Phase 2·NCT05783076·29 enrolled
Stereotactic Body Radiation Therapy1 trial
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
Active, not recruiting·—·Phase 2·NCT02880319·150 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRoswell Park Cancer Institute